Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.